About Us

Adverum Biotechnologies is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.

Mission

Our Global Mission

To establish gene therapy as a new standard of care for the leading causes of vision loss.

Core Values

We are doing what’s never been done before driven by a higher purpose to go beyond – to develop and deliver functional cures for debilitating ocular diseases. We take pride in the work we do, and we take heart in the way we do it.

Lead with Integrity

We take individual and collective responsibility to put patients first and to make evidence-based decisions as we embark on a bold mission.

Pioneer with Patients

We use our science, technology, and expertise to innovate and optimize breakthrough products that preserve the sight of patients across the globe.

Strive Together

We aim high, tackling complex issues through diversity of perspectives, shared decision-making, and collaboration.

Sustainability

At Adverum, our values define how we conduct business, shape patient care, apply science to medicine, and work and grow as a company. We strive to put our corporate values into action every day – by reducing the environmental impact of our research and operations, providing safe, engaging and impactful work for our employees, and always leading with integrity.

To learn more, click here.

Sustainability Oversight

We integrate environmental, social, and governance objectives into our decision-making to deliver long-term value to all of our stakeholders. Our leadership creates and monitors our sustainability-related programs, with our board of directors maintaining ultimate oversight.

To identify the sustainability issues material to our business, we are guided by best practices, feedback we receive from our stakeholders, including employees, regulators, patients and investors, and third-party thought leaders, such as the Sustainability Accounting Standards Board (SASB), Biotechnology and Pharmaceuticals.

Our Board of Directors has four standing committees: an Audit Committee, a Compensation Committee, a Nominating & Corporate Governance Committee and a Research & Development Committee.

The following table provides membership information for each committee.

Name Audit Committee Compensation Committee Nominating & Corporate Governance Committee Research & Development Committee
Laurent Fischer, M.D.
Soo Hong
Mark Lupher, Ph.D.
Patrick Machado
Rabia Gurses Ozden, M.D.
James Scopa
Dawn Svoronos
Reed Tuckson, M.D.
Scott Whitcup, M.D.

Audit Committee

Patrick Machado

James Scopa

Dawn Svoronos

Compensation Committee

Soo Hong

Patrick Machado

James Scopa

Reed Tuckson, M.D.

Nominating & Corporate Governance Committee

Mark Lupher, Ph.D.

Dawn Svoronos

Reed Tuckson, M.D.

Scott Whitcup, M.D.

Research & Development Committee

Mark Lupher, Ph.D.

Rabia Gurses Ozden, M.D.

Scott Whitcup, M.D.

Chairperson of the Board

Committee Chairperson

Committee Member

Print All

Join the Team

Working at Adverum

Join our team of visionaries and disruptors to see beyond each breakthrough and help patients live their lives fully – in vision, action, and expression.